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Precis: Our results from a diverse, population-based sample show that nearly half of women 
treated for early stage breast cancer experienced at least one toxicity they rated as severe/very 
severe during treatment, with variation observed by treatment modality. Toxicities correlate with 
physical function and increased healthcare service use. 
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ABSTRACT 
Background 
Patient-reported toxicities help to appraise the breast cancer treatment experience. Yet extant 
data come from clinical trials and healthcare claims, which may be biased. Using patient surveys, 
we sought to quantify the frequency, severity, and burden of treatment-associated toxicities.  
Methods  
Between 2013 and 2014, the iCanCare study surveyed a population-based sample of women 
residing in Los Angeles County and Georgia with early-stage, invasive breast cancer. We 
assessed the frequency and severity of toxicities, correlated toxicity severity with unscheduled 
healthcare use (clinic visits, emergency department visits/hospitalization) and physical health, 
and examined patient, tumor, and treatment factors associated with reporting increased toxicity 
severity.  
Results 
The overall survey response was 71%. From the analyzed cohort of 1,945 women, 866 (45%) 
reported at least one toxicity that was severe/very severe, 9% reported unscheduled clinic visits 
for toxicity management, and 5% visited an emergency department or hospital. Factors 
associated with reporting higher toxicity severity included: chemotherapy receipt (OR 2.2, 95% 
CI 2.0-2.5), both chemotherapy and radiation therapy receipt (OR 1.3, 95% CI 1.0-1.7), and 
Latina ethnicity (OR vs whites 1.3, 95% CI 1.1-1.5). A non-significant increase in at least one 
severe/very severe toxicity report was observed for bilateral mastectomy recipients (OR 1.2, 95% 
CI 1.0-1.4).  
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Conclusions 
Women with early-stage invasive breast cancer report substantial treatment-associated toxicities 
and related burden. Clinicians should collect toxicity data routinely and offer early intervention. 
Toxicity differences by treatment modality may inform decision-making. 
 
Key words: Breast Cancer; treatment experience; treatment-associated toxicities; patient report 
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INTRODUCTION 
Cancer treatments have a narrow therapeutic index. Clinicians constantly weigh 
anticipated benefits of anti-cancer treatments against risks of treatment-associated toxicities. 
Toxicities may lead to treatment discontinuation,1,2 costly healthcare service use,3 and premature 
death.4 Toxicities place physical, emotional, and financial burdens on patients and families.5 
Toxicity management also consumes clinician and practice resources.6 
 Despite the burdens placed on patients, families, and healthcare systems, few data 
sources capture toxicities reliably. Treatment-related toxicity studies generally derive from 
clinical trials data,7 health care claims,8 and single-site patient registries,9 with notable 
limitations of generalizability, data quality, and biased reporting. In 2007, a National Cancer 
Institute-sponsored working group developed a patient-reported version of the Common 
Terminology Criteria for Adverse Events (CTCAE). The Patient-Reported Outcomes version of 
the CTCAE (PRO-CTCAE) enables patients to report the frequency, severity, and burden of 
toxicities and addresses well-documented biases observed with clinician-reported toxicity 
ratings. 10,11 
Few studies have solicited the toxicity experience directly from diverse, population-based 
patient samples. Describing the patterns, correlates, and frequency of treatment-associated 
toxicities from a large population-based sample allows clinicians to understand the actual patient 
treatment experience outside the narrow confines of rigorously-conducted clinical trials. Such 
data could inform targeted, proactive efforts to identify patients at risk for burdensome toxicities, 
enable earlier intervention, and improve quality of life. 
In this context, we analyzed data collected from a population-based survey of women 
diagnosed with early-stage invasive breast cancer. We examined frequency and severity of 
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toxicities associated with cancer treatment. Next, we explored the correlation between toxicity 
reports and physical health and healthcare service use. Finally, we examined patient, tumor, and 
treatment factors associated with toxicities rated as severe or very severe.  
PATIENTS AND METHODS 
SAMPLING AND SURVEY PROCEDURES 
The iCanCare study is a population-based mailed survey of women with early-stage 
breast cancer. In partnership with the Los Angeles County and Georgia Surveillance 
Epidemiology and End-Results (SEER) programs, the iCanCare study identified 3,880 women of 
ages 20 through 79 years who were diagnosed with early-stage breast cancer determined by a 
definitive breast surgery date between July 1, 2013 and December 31, 2014. Women were sent 
surveys about 2 months after surgery and completed the survey on average about 7 months after 
diagnosis. To enable meaningful analyses across racial and ethnic groups, African Americans 
and Latinas were oversampled in Los Angeles County. The following women were excluded 
from the iCanCare study sampling protocol: stage III or IV cancer (as the overall project was 
focused on early-stage patients), Paget’s disease, or tumors > 5cm in size. In Los Angeles 
County, non-Hispanic whites and African Americans aged <50 were excluded due to a 
competing study in these populations.  
The study was approved by the Institutional Review Boards of the University of 
Michigan and partnering institutions. Informed by Dillman’s methods,12 we solicited 
participation with a $20 cash incentive. Study coordinators in respective geographic areas 
continued to follow up with non-responders, including up to 9 attempted phone calls and 2 
repeated mailings. Participants received survey materials to their home address with a statement 
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that their answers would not be shared individually with their providers. Study materials were 
printed in English; women with Spanish surnames received Spanish and English materials.13 
Of 3,880 originally-identified women, 249 were ineligible. From these 3,631 women, 
1,053 women were not reached or did not return questionnaires, resulting in an overall response 
rate of 71% (n=2,578). After excluding 694 women with DCIS or bilateral disease our analytic 
sample included 1,884 observations in the observed data and 1,945 observations after multiple 
imputation. SEER registries linked surveys to standardized tumor registry data.  
MEASURES 
Except where indicated, measures were collected from patient questionnaires. The 
primary outcome was treatment-associated toxicities. Informed by the PRO-CTCAE working 
group14 and our pilot work,15 participants rated the severity of seven toxicities – at their worst 
during cancer treatment – using a 5-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = 
severe, 4 = very severe). The toxicities measured were nausea/vomiting, diarrhea, constipation, 
pain, arm edema, dyspnea, and breast skin irritation. These toxicities were selected after 
interviews with survivors and analysis of toxicity reports in pilot work.15  
As few studies have investigated patient-reported, treatment-associated toxicities, we 
measured toxicities in three ways. First, we examined the range of severity ratings across 
toxicities. Next, we constructed a scale by multiplying the number of toxicities reported by 
severity. For example, a score of 3 might reflect one toxicity rated as severe or three toxicities 
rated as mild, and a score of 28 would reflect that a patient reported all seven toxicities as very 
severe.  
To examine toxicity burden, we examined physical health and healthcare service use. To 
measure physical health, we used the 4-item physical function subscale of the Patient Reported 
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Outcome Measurement Information System (PROMIS) global health measure. The scale is a 
brief, valid, reliable, precise, and clinically interpretable measure of physical health.16 
Respondents rated each item on a 5-point ordinal scale. The score was standardized and 
normalized according to the scoring manual; scores below 40 reflected poor physical health.17 To 
measure healthcare service use, we asked patients whether they 1) did not seek help, 2) 
called/emailed their provider, 3) discussed at a routine visit, 4) discussed at an unscheduled visit, 
or 5) visited the emergency department/hospital. We classified unscheduled care as either an 
unscheduled clinic visit, emergency department visit, or inpatient hospitalization for toxicity 
management. 
Patients reported their age, race/ethnicity (white, black, Latina, Asian), education (high 
school or less, some college, college graduate or more), and prior comorbidity diagnosis– 
chronic lung disease, heart disease, diabetes, or stroke – (no diagnosis, one condition, two or 
more conditions). We included four separate variables to capture treatment factors: primary 
breast surgery (lumpectomy, unilateral mastectomy, bilateral mastectomy), radiation therapy 
(yes/no), systemic chemotherapy (yes/no), and receipt of both radiation and chemotherapy 
(yes/no). SEER registries provided tumor information: stage (I or II), grade (1, 2, or 3), and 
lymph node status (N0 or N1). We calculated the difference between the date of patient survey 
completion and the cancer diagnosis date. 
ANALYSIS 
First, we used descriptive statistics to examine patient, disease, and treatment factors in 
our analytic sample and then examined these factors in the subset of women who rated at least 
one toxicity as severe/very severe, as well as in the subset of women who reported unscheduled 
care for toxicity management.  Next, for each of the seven toxicities and corresponding severity 
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rating, we calculated the proportion of women who also reported healthcare service use (phone 
call, scheduled visit, unscheduled visit, emergency department visit/hospitalization) for that 
toxicity. Using the multiplied scale of number of toxicities reported by their severity, we next 
plotted the corresponding PROMIS physical function scores. Using multivariable regression, we 
examined two dependent variables – unscheduled care and PROMIS physical function scores - 
by toxicity score, controlling for patient, tumor, and treatment factors. Finally, we used 
multivariable ordinal logistic regression with design weights reflecting the probability of 
selection and non-response to examine the relationship of patient, tumor, and treatment factors to 
higher levels of toxicity severity.  
Unless specified, analyses controlled for geography (Los Angeles County and Georgia) 
and were weighted to account for differing probabilities of sample selection and non-response.18 
We identifie  small amounts of missing data (range of 0-3.9% across variables, 93% of 
observations had complete data). To minimize biased estimates from missing data, we applied a 
sequential regression multiple imputation framework.19 We generated five independently-
imputed data sets and computed inferential statistics that combined analyses across datasets.20 
Imputation results were indistinguishable from the complete case analysis. Table 1 is based on 
complete case analysis (N identified in table for each variable) and all subsequent figures and 
regression results are based on multiply-imputed data (N=1,945).  
RESULTS 
Table 1 shows patient characteristics, including women who reported any of the seven 
measured toxicities as severe/very severe, and those who sought unscheduled care for toxicities 
via clinic visits, emergency departments, or hospitals.  
Frequency and Severity of Patient-Reported Toxicities. 
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Women with early-stage invasive breast cancer reported a number of toxicities during 
treatment, many of which were rated as severe or very severe. 132 patients (7%) reported that 
none of the seven toxicities occurred during treatment. 1,810 women (93%) reported at least one 
toxicity and 866 of the women in the analytic sample (45%) rated at least one toxicity as 
severe/very severe. Among the seven toxicities, pain was most frequently reported as severe/very 
severe (23%), followed by constipation (14%), and breast skin irritation (13%). 
Toxicities and Healthcare Service Use. 
Figure 1 shows patient reports of healthcare service use by each toxicity studied and the 
corresponding severity rating. Across all seven toxicities, 2-4% of patients did not endorse a 
toxicity rating, but discussed the problem during a routine office visit. Most patients sought help 
during an office visit (range between 22% and 77% across the seven toxicities); telephone 
calls/emails and emergency department visits/hospitalizations were less frequently reported. For 
women who experienced at least one toxicity, 9% sought care through a previously unscheduled 
clinic visit and 5% visited an emergency department or hospital.  
Nausea/vomiting and diarrhea were frequent sources of telephone calls/emails; 29% of 
patients with very severe nausea/vomiting and 27% of patients with very severe diarrhea called 
or emailed their provider. Severe arm edema (77%) and very severe skin irritation (71%) were 
the primary reasons for unscheduled clinic visits. Patients with severe/very severe dyspnea most 
frequently visited emergency departments or hospitals for toxicity management (28%), followed 
by patients with severe/very severe arm edema (27%), severe/very severe diarrhea (18%), and 
severe/very severe pain (18%). 
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Toxicities and Physical Health. 
The mean (SD) physical functioning score on the PROMIS measure was 14.5 (3), 
reflecting substantial deficits from the optimal score of 50. Figure 2 shows the relationship 
between the multiplied toxicity rating (number of toxicities and toxicity severity rating) and 
PROMIS physical scores estimated by a regression model, with corresponding 95% confidence 
intervals. Higher PROMIS scores reflect better physical functioning and higher toxicity scores 
reflect more frequent and/or severe toxicity ratings These scores were averaged across age, 
comorbid conditions, chemotherapy receipt, employment, marital status, and race/ethnicity. 
PROMIS-physical functioning scores correlated linearly, negatively, and significantly with 
toxicity ratings (β = -0.2, 95% CI -0.3 - -0.2). Patients without toxicity had the highest scores, 
whereas patients who reported all seven toxicities as severe reported scores at the lowest possible 
score of 10 on the scale  
Factors Associated with Reporting at Severe or Very Severe Toxicity. 
Figures 3A-C show the unadjusted differences in toxicity reporting by breast cancer 
treatment. Toxicity severity varied by chemotherapy receipt (Figure 3A). For example, 29% of 
chemotherapy recipients reported severe/very severe pain, compared with 19% of women who 
did not receive chemotherapy. Severe/very severe constipation was reported by 24% of 
chemotherapy recipients, compared with rates of 9% for women who did not receive 
chemotherapy. Radiation therapy recipients reported more severe/very severe skin irritation than 
women who did not receive radiation (22% versus 7%), but did not differ on other toxicities 
(Figure 3B). 
Toxicity severity varied by surgical treatment (Figure 3C). For five of seven toxicities 
studied, women who received bilateral mastectomy were more likely to report more 
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severe/severe toxicities (nausea/vomiting, diarrhea, constipation, pain, and shortness of breath). 
More bilateral mastectomy recipients (37%) reported severe/very severe pain than those 
receiving unilateral mastectomy (25%) or lumpectomy (18%).  
Figure 4 shows the results of a multivariable logistic regression model, which shows 
significant associations between the category of toxicity, plus patient and treatment factors 
associated with the severity toxicity. We also included a variable to reflect patient receipt of both 
chemotherapy and radiation therapy. Three toxicities were more frequently associated with more 
severe ratings; pain (OR 4.7, 95% CI 4.2-5.3), skin irritation (OR 2.1, 95% CI 1.8-2.5), and 
constipation (OR 1.5, 95% CI 1.4-1.7). Women who received systemic adjuvant chemotherapy 
were more likely to report more severe toxicity (OR 2.0, 95% CI 1.7-2.4). Patients who received 
both chemotherapy and radiation therapy had an additional 30% higher odds of more severe 
toxicity (OR 1.3, 95% CI 1.0-1.7) over those receiving only chemotherapy. Patients who had 
bilateral mastectomy were more likely to report higher toxicity (OR 1.2, 95% CI 1.0-1.4) than 
unilateral mastectomy recipients, but the difference did not reach statistical significance.  
Older patients were significantly less likely to report higher toxicity (OR 0.8, 95% CI 
0.7-0.8). Patients with more comorbidities were more likely to report higher toxicity (OR 1.4 
95% CI 1.3-1.5 for the first comorbidity). Latinas were more likely than white women to report 
higher toxicity (OR 1.3, 95% CI 1.1-1.5). Compared with college graduates, women with some 
college education were more likely to report higher toxicity (OR 1.2, 95% CI 1.0-1.3).  
DISCUSSION 
In this population-based sample of women with early-stage, invasive breast cancer, a 
substantial number of patients reported clinically-burdensome toxicities during treatment. A 
scaled measure that captured the number and severity of toxicities was associated with poorer 
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physical health and increased healthcare service use, including unscheduled clinic visits, 
emergency department visits, and inpatient admissions. Compared to those without severe 
toxicities, women who reported at least one severe toxicity differed in age, comorbidity history, 
race/ethnicity, and breast cancer treatment. These novel data solicited directly from patients 
highlight opportunities to improve supportive care through targeted toxicity management and 
data-informed patient-provider communication. 
High rates of burdensome toxicities reported by women with early-stage breast cancer 
support recent assertions that many women with curable disease suffer “collateral damage” from 
breast cancer treatment.21 Nearly one quarter of chemotherapy recipients in our study endorsed 
severe/very severe nausea/vomiting during their cancer treatment. This finding likely reflects 
inconsistent adoption of chemotherapy-induced nausea and vomiting guidelines across diverse 
chemotherapy settings.22 It is unclear whether patients receive standardized education about 
toxicities expected during treatment. Targeting toxicities that occur frequently and are reported 
as severe or very severe is one important clinical intervention to improve outcomes for women 
with early-stage breast cancer.  
Importantly, toxicity severity correlates with clinically significant physical health 
deficits. Breast cancer survivorship guidelines stress the importance of optimal physical health 
for breast cancer survivors.23 Our data suggest burdensome toxicities occur in patients who do 
not receive chemotherapy and interfere with physical health, which may threaten long-term 
outcomes. Supportive care programs that extend beyond chemotherapy recipients are needed to 
reduce toxicity severity, maintain health, and enhance the survivorship period. For example, 
routine toxicity assessments across chemotherapy, surgery, and radiation therapy clinics would 
identify high-priority areas for interventions. 
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Our findings are congruent with a prospective study of Italian women recently diagnosed 
with breast cancer and treated with adjuvant systemic therapy who completed similar patient-
reported toxicity measures.24 High rates of gastrointestinal symptoms were reported. Compared 
with the current study, lower rates of pain were reported. In a small, longitudinal study of women 
receiving doxorubicin-based chemotherapy for early stage breast cancer, the most frequent, 
severe, and distressing physical symptoms reported included pain.25 The differences observed 
may be due to the different survey time points or survey prompts; on average, participants in the 
iCanCare study completed surveys 7 months after definitive breast surgery. In the survey, 
women rated the severity of their toxicities at their worst during treatment. While prior work 
suggests patient recall of toxicities is valid and reliable,26 we cannot exclude the possibility of 
recall bias.  
Our finding of higher toxicity burdens for non-white patients may explain prior findings 
of lingering quality of life deficits for Latinas with breast cancer;27 culturally-sensitive toxicity 
management interventions may be warranted. Women may perceive that bilateral mastectomy is 
associated with improved survival and minimal difference in other outcomes.28 Our data suggest 
that bilateral mastectomy recipients experience more toxicity severity relative to other surgical 
options; pain reports are nearly double those compared with women who receive lumpectomy. 
Decision aids for women that present patient-reported outcome rates across surgical modalities 
may bridge knowledge gaps. If women were aware of the pain differences reported by procedure, 
their treatment preferences may differ. Given the differential effects of chemotherapy and 
radiation therapy, it is not surprising that women who received both of these treatments reported 
higher toxicity severity than uni-modal treatment; targeted interventions may be warranted in 
women who receive multi-modal treatment. 
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Patients and providers seek to boost the value of cancer care services. Despite excellent 
survival rates, cancer treatment often leads to costly toxicity management, including emergency 
department visits and hospitalizations,29 and unscheduled clinic visits that strain busy clinicians. 
Cancer care value may improve if toxicities can be managed proactively, before they worsen. 
Researchers have examined the efficacy of routine toxicity assessments coupled with notification 
of aberrant results to providers, with mixed results.29,30 Our results underscore the need for 
further research that examine novel strategies to reduce preventable treatment toxicities.  
  Strengths of our study include an excellent response rate, a diverse patient sample, and 
patient-centered measures of toxicity and healthcare service use. Unlike chart review and claims-
based approaches, our use of patient-reported measures may overcome documented concerns for 
clinician reporting of toxicities31 and measurement challenges in healthcare claims.8 However, 
several aspects of our study merit comment. First, our data are cross sectional and causal 
relationships cannot be assumed. We did not have access to medical records to ascertain 
regimens, dosages, and timing of chemotherapy and radiation, nor do we have clinician reports 
of toxicities and health care service use, which could address concerns for patient recall. The 
survey timing should be considered when interpreting toxicity reports and healthcare service use. 
While our work was informed by the NCI’s PRO-CTCAE working group,14 the study measures 
are not identical in terms of timing of administration and rating categories. While the regions 
studied are diverse, results may not be generalizable to other settings. Given the overall project 
goal of understanding treatment patterns in early-stage breast cancer, our results are germane to 
patients with early-stage disease; similar investigations in patients with advanced disease, would 
identify toxicity frequency and intensity in the setting of more frequent multi-modal treatments. 
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Nearly half of women with early-stage, invasive breast cancer experience toxicities they 
perceive as severe or very severe, including women who do not receive adjuvant systemic 
chemotherapy. These findings have important clinical implications. The toxicity burden faced by 
patients may be greater than acknowledged by clinicians, and warrants routine assessment during 
and between clinic visits. Differential toxicity patterns identified in this diverse, population-
based sample of women may help clinicians when they review risks and benefits of breast cancer 
treatment options. Data-driven patient education and communication tools that compare patient-
reported outcomes from breast cancer treatments could inform decision making and prepare 
women for the treatment experience. Pain control is challenging for many women across diverse 
treatment plans. Gastrointestinal toxicities plague chemotherapy recipients despite available 
practice guidelines. Additional studies must help clinicians distinguish the duration of treatment-
associated toxicities and their impact on therapy completion. Finally, our data speak to the need 
for culturally-tailored interventions coupled with management protocols to improve quality of 
life for patients at risk for burdensome toxicities. 
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Figure Legends 
 
Figure 1: Distribution of Patient-Reported Healthcare Service use by Each Toxicity and Rated 
Severity 
ER=Emergency Room. Results reported are based on weighted, imputed data. 
 
Figure 2: Physical Health Scores by Toxicity Severity 
PROMIS=Patient-Reported Outcomes Measurement Information System. Higher physical health 
scores reflect better physical functioning. Higher toxicity severity scores reflect increased toxicity 
frequency and/or worse severity. Toxicity scores were inversely proportional to physical health (β = -
0.2, 95% CI -0.3 - -0.2). Results reported are based on weighted, imputed data. 
 
Figures 3A-C: Toxicity Severity by Breast Cancer Treatment. 
3A: Differences in toxicity severity by chemotherapy receipt. N=1,945 
3B: Differences in toxicity severity by radiation therapy receipt. N=1,945 
3C: Differences in toxicity severity by breast cancer surgery. N=1,945 
Results reported are based on weighted, imputed data. 
 
Figure 4: Factors Associated with Reporting More Severe Toxicities 
GED=Graduate equivalent diploma. Dbl. mast=Bilateral mastectomy. Results reported are based on 
weighted, imputed data. Note: the odds ratio represents the odds of being in a higher vs. a lower 
level of toxicity severity.    
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Table 1: Patient Sample Characteristics by Toxicity Report and Report of Healthcare 
Service Use 
 N Reported one or 
more toxicities as 
severe or very severe 
Sought unscheduled 
care (clinic visit, 
Emergency 
Department, or 
Hospital) 
    
Age (years), Mean 1,884 60 59 
Diagnosis to survey (days), 
Mean 
1,878 207 218 
    Percent 
PATIENT FACTORS    
Race/Ethnicity    
White 1,057 40 11 
Black 321 52 16 
Latina 315 53 17 
Asian 141 48 6 
Other/unknown/missing 50 52 17 
Education    
Less than high school 211 57 16 
High school graduate 331 37 9 
Some college 623 48 12 
College graduate or more 698 42 13 
Comorbidites    
0 1,101 41 12 
1 527 49 13 
2 or more 247 52 15 
      
TUMOR FACTORS    
Stage    
1 1,264 41 11 
2 620 52 16 
Lymph nodes positive    
No 1,502 42 11 
Yes 382 53 18 
      
TREATMENT FACTORS    
Surgical treatment    
Lumpectomy 1,138 39 12 
Unilateral Mastectomy 393 48 12 
Bilateral Mastectomy 338 58 16 
Radiation treatment    
No/future radiation 975 51 14 
Current/past radiation 890 37 11 
Adjuvant chemotherapy    
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No chemotherapy 1,134 35 8 
Chemotherapy 736 60 19 
Received both chemotherapy 
and radiation therapy     
No 1,667 43 12 
Yes 217 59 19 
    
Site    
Georgia 1,049 42 12 
Los Angeles County 835 47 13 
Data are n (%), mean (SD), unless otherwise stated. Percentages are based on unweighted data. 
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Figure 1: Distribution of Patient-Reported Healthcare Service use by Each Toxicity and Rated Severity  
ER=Emergency Room. Results reported are based on weighted, imputed data.  
Figure 1 shows patient reports  
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Figure 2: Physical Health Scores by Toxicity Severity  
PROMIS=Patient-Reported Outcomes Measurement Information System. Higher physical health scores 
reflect better physical functioning. Higher toxicity severity scores reflect increased toxicity frequency and/or 
worse severity. Toxicity scores were inversely proportional to physical health (β = -0.2, 95% CI -0.3 - -0.2). 
Results reported are based on weighted, imputed data.  
Figure 2 shows the relationshi  
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Figures 3A-C: Toxicity Severity by Breast Cancer Treatment.  
3A: Differences in toxicity severity by chemotherapy receipt. N=1,945  
Toxicity severity varied by ch  
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Figures 3A-C: Toxicity Severity by Breast Cancer Treatment.  
3B: Differences in toxicity severity by radiation therapy receipt. N=1,945  
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Figures 3A-C: Toxicity Severity by Breast Cancer Treatment.  
3C: Differences in toxicity severity by breast cancer surgery. N=1,945  
Results reported are based on weighted, imputed data.  
Toxicity severity varied by su  
66x48mm (300 x 300 DPI)  
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Figure 4: Factors Associated with Reporting More Severe Toxicities  
GED=Graduate equivalent diploma. Dbl. mast=Bilateral mastectomy. Results reported are based on 
weighted, imputed data. Note: the odds ratio represents the odds of being in a higher vs. a lower level of 
toxicity severity.    
Figure 4 shows the results of  
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